In a stunning move to the cannabis business world, industry giant Canopy Growth (TSX:WEED; NYSE:CGC) announced on Tuesday (July 10) it will acquire the brand and retail-focused Hiku Brands (CSE:HIKU). 

This new deal will cause the termination of the Hiku and WeedMD (TSXV:WMD) merge that would’ve seen the combination of a medical producer and a brand-focused company.

Keep reading... Show less

On Monday (June 25) various hopefuls and established names of the Canadian cannabis industry gathered for the International Cannabis Business Conference (ICBC) held in Vancouver.

Hosted by ICBC, the Vancouver iteration of this event offered a variety of panels of interest for investors of the cannabis space. The Investing News Network (INN) was there at the show attending numerous panel discussions and gaining further insight into the future of the Canadian cannabis space.

Keep reading... Show less

If you’re looking to invest in stocks, the TSX Venture 50 is always a good place to start.
With that in mind, every year the TSXV releases a list of companies it considers its top 50. Companies are chosen based on three equally weighted criteria: market cap growth, share price appreciation and trading volume.
That said, biotech and pharmaceutical companies weren’t as prominent on this year’s list. Instead, here the Investing News Network highlights the impact medical cannabis companies had in entering this space.
Here’s a closer look at those companies.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Aphria (TSXV:APH)

Aphria is a major player in the medical marijuana sector throughout Canada. Their products include various types of cannabis, greenhouse grown, according to Health Canada’s guidelines.
In late April 2017, the company raised $100 million in funds to expand their production–$75 million of which is a bought deal financing, while the remainder is a debt financing over a five-year loan. According to the press release, 50 percent of the proceeds are expected to go towards the unfunded portion of Part IV Expansion, while the balance will go towards the working capital needed to support Aphria once the Part IV expansion is done.

Emerald Health Therapeutics (TSXV:EMH)

Licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR), Emerald Health Therapeutics cultivates medical marijuana in addition to selling a variety of dried cannabis and oils. The company’s wholly-owned subsidiary, Emerald Health Botanicals is a licensed producer of medical marijuana in Canada.
In mid-April 2017, the company expanded a previously announced bought deal financing from Eight Capital to $24.4 million.

OrganiGram (TSXV:OGI)

OrganiGram came onto the scene in 2013 as an organic medical cannabis  company. Now, it is in the middle of a number of controversies. Following a recall for products sold in 2016, the company is preparing to defend itself in a lawsuit over the discovery of pesticides in their crops.
That said, in early April 2017, the company announced it had entered into a letter of intent to acquire Trauma Healing Centers.  According to the press release, the two companies have worked together over the last two years in some capacity, and look forward to growing in the fast-paced Canadian cannabis sector.

Ceapro (TSXV:CZO)

Ceapro is a biotechnology company that provides “green” ingredients to manufacturers of personal care products, nutraceuticals, and developers of therapeutics. The company is developing proprietary extraction technology and its applications to the production of extracts from oats and other renewable plant resources.
In early April, the company released its 2016 financial results, highlighting total sales of $13,674,000, compared to $10,667,000 in 2015, representing a 28.2 percent increase over the year.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
Keep reading... Show less